Literature DB >> 18199703

CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation.

Claudia R Amura1, Kelley S Brodsky, Berenice Gitomer, Kim McFann, Gwendal Lazennec, Matthew T Nichols, Alkesh Jani, Robert W Schrier, R Brian Doctor.   

Abstract

Autosomal dominant polycystic kidney disease (ADPKD) is a highly prevalent genetic disease that results in cyst formation in kidney and liver. Cytokines and growth factors secreted by the cyst-lining epithelia are positioned to initiate autocrine/paracrine signaling and promote cyst growth. Comparative analyses of human kidney and liver cyst fluids revealed disparate cytokine/growth factor profiles. CXCR2 agonists, including IL-8, epithelial neutrophil-activating peptide (ENA-78), growth-related oncogene-alpha (GRO-alpha), are potent proliferative agents that were found at high levels in liver but not kidney cyst fluids. Liver cysts are lined by epithelial cells derived from the intrahepatic bile duct (i.e., cholangiocytes). In polarized pkd2(WS25/-) mouse liver cyst epithelial monolayers, CXCR2 agonists were released both apically and basally, indicating that they may act both on the endothelial and epithelial cells within or lining the cyst wall. IL-8 and human liver cyst fluid induced cell proliferation of HMEC-1 cells, a human microvascular endothelial cell line, and Mz-ChA1 cells, a human cholangiocyte cell model. IL-8 expression can be regulated by specific stresses. Hypoxia and mechanical stretch, two likely stressors acting on the liver cyst epithelia, significantly increased IL-8 secretion and promoter activity. AP-1, c/EBP, and NF-kappaB were required but not sufficient to drive the stress-induced increase in IL-8 transcription. An upstream element between -272 and -1,481 bp allowed for the stress-induced increase in IL-8 transcription. These studies support the hypothesis that CXCR2 signaling promotes ADPKD liver cyst growth.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18199703      PMCID: PMC2956747          DOI: 10.1152/ajpcell.00457.2007

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  45 in total

1.  Somatic inactivation of Pkd2 results in polycystic kidney disease.

Authors:  G Wu; V D'Agati; Y Cai; G Markowitz; J H Park; D M Reynolds; Y Maeda; T C Le; H Hou; R Kucherlapati; W Edelmann; S Somlo
Journal:  Cell       Date:  1998-04-17       Impact factor: 41.582

2.  Reorganization of cholangiocyte membrane domains represents an early event in rat liver ischemia.

Authors:  R B Doctor; R H Dahl; K D Salter; J G Fitz
Journal:  Hepatology       Date:  1999-05       Impact factor: 17.425

3.  Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways.

Authors:  H Holtmann; R Winzen; P Holland; S Eickemeier; E Hoffmann; D Wallach; N L Malinin; J A Cooper; K Resch; M Kracht
Journal:  Mol Cell Biol       Date:  1999-10       Impact factor: 4.272

4.  Stretch induces cytokine release by alveolar epithelial cells in vitro.

Authors:  N E Vlahakis; M A Schroeder; A H Limper; R D Hubmayr
Journal:  Am J Physiol       Date:  1999-07

5.  The CXC chemokine receptor 2, CXCR2, is the putative receptor for ELR+ CXC chemokine-induced angiogenic activity.

Authors:  C L Addison; T O Daniel; M D Burdick; H Liu; J E Ehlert; Y Y Xue; L Buechi; A Walz; A Richmond; R M Strieter
Journal:  J Immunol       Date:  2000-11-01       Impact factor: 5.422

6.  Regulation of disease-progression genes in human gastric carcinoma cells by interleukin 8.

Authors:  Y Kitadai; K Haruma; N Mukaida; Y Ohmoto; N Matsutani; W Yasui; S Yamamoto; K Sumii; G Kajiyama; I J Fidler; E Tahara
Journal:  Clin Cancer Res       Date:  2000-07       Impact factor: 12.531

7.  Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities.

Authors:  H B Lowman; P H Slagle; L E DeForge; C M Wirth; B L Gillece-Castro; J H Bourell; W J Fairbrother
Journal:  J Biol Chem       Date:  1996-06-14       Impact factor: 5.157

8.  Location of mutations within the PKD2 gene influences clinical outcome.

Authors:  N Hateboer; B Veldhuisen; D Peters; M H Breuning; J L San-Millán; N Bogdanova; E Coto; M A van Dijk; A R Afzal; S Jeffery; A K Saggar-Malik; R Torra; D Dimitrakov; I Martinez; S S de Castro; M Krawczak; D Ravine
Journal:  Kidney Int       Date:  2000-04       Impact factor: 10.612

9.  Transactivation of vascular endothelial growth factor receptor-2 by interleukin-8 (IL-8/CXCL8) is required for IL-8/CXCL8-induced endothelial permeability.

Authors:  Melissa L Petreaca; Min Yao; Yan Liu; Kathryn Defea; Manuela Martins-Green
Journal:  Mol Biol Cell       Date:  2007-10-10       Impact factor: 4.138

10.  Epidermal growth factor and endothelin in cyst fluid from autosomal dominant polycystic kidney disease cases: possible evidence of heterogeneity in cystogenesis.

Authors:  C Munemura; J Uemasu; H Kawasaki
Journal:  Am J Kidney Dis       Date:  1994-10       Impact factor: 8.860

View more
  10 in total

Review 1.  Autosomal dominant polycystic kidney disease: the last 3 years.

Authors:  Vicente E Torres; Peter C Harris
Journal:  Kidney Int       Date:  2009-05-20       Impact factor: 10.612

Review 2.  Regulation of biliary proliferation by neuroendocrine factors: implications for the pathogenesis of cholestatic liver diseases.

Authors:  Md Kamruzzaman Munshi; Sally Priester; Eugenio Gaudio; Fuquan Yang; Gianfranco Alpini; Romina Mancinelli; Candace Wise; Fanyn Meng; Antonio Franchitto; Paolo Onori; Shannon S Glaser
Journal:  Am J Pathol       Date:  2011-02       Impact factor: 4.307

Review 3.  Polycystic liver diseases: advanced insights into the molecular mechanisms.

Authors:  Maria J Perugorria; Tatyana V Masyuk; Jose J Marin; Marco Marzioni; Luis Bujanda; Nicholas F LaRusso; Jesus M Banales
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2014-09-30       Impact factor: 46.802

4.  Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2.

Authors:  Kameswaran Ravichandran; Abdullah Ozkok; Qian Wang; Adam E Mullick; Charles L Edelstein
Journal:  Am J Physiol Renal Physiol       Date:  2014-12-23

5.  Complement activation and toll-like receptor-2 signaling contribute to cytokine production after renal ischemia/reperfusion.

Authors:  Claudia R Amura; Brandon Renner; Taras Lyubchenko; Sarah Faubel; Philip L Simonian; Joshua M Thurman
Journal:  Mol Immunol       Date:  2012-06-27       Impact factor: 4.407

Review 6.  Polycystic liver diseases.

Authors:  P Onori; A Franchitto; R Mancinelli; G Carpino; D Alvaro; H Francis; G Alpini; E Gaudio
Journal:  Dig Liver Dis       Date:  2010-02-06       Impact factor: 4.088

7.  Inhibition of metalloprotease hyperactivity in cystic cholangiocytes halts the development of polycystic liver diseases.

Authors:  Aura D Urribarri; Patricia Munoz-Garrido; María J Perugorria; Oihane Erice; Maite Merino-Azpitarte; Ander Arbelaiz; Elisa Lozano; Elizabeth Hijona; Raúl Jiménez-Agüero; Maite G Fernandez-Barrena; Juan P Jimeno; Marco Marzioni; Jose J G Marin; Tatyana V Masyuk; Nicholas F LaRusso; Jesús Prieto; Luis Bujanda; Jesús M Banales
Journal:  Gut       Date:  2014-01-16       Impact factor: 23.059

Review 8.  Cholangiociliopathies: genetics, molecular mechanisms and potential therapies.

Authors:  Tatyana Masyuk; Anatoliy Masyuk; Nicholas LaRusso
Journal:  Curr Opin Gastroenterol       Date:  2009-05       Impact factor: 3.287

9.  Pkd2 dosage influences cellular repair responses following ischemia-reperfusion injury.

Authors:  Sony Prasad; John Patrick McDaid; Frederick Wai Keung Tam; John Lionel Haylor; Albert Chee Meng Ong
Journal:  Am J Pathol       Date:  2009-09-03       Impact factor: 4.307

Review 10.  Development of the bile ducts: essentials for the clinical hepatologist.

Authors:  Mario Strazzabosco; Luca Fabris
Journal:  J Hepatol       Date:  2012-01-13       Impact factor: 25.083

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.